Reshoring and nearshoring medical device and consumable manufacturing back to North America has been a consistent talking point since the supply disruptions of recent years, amplified further by escalating tariffs on Asian manufacturing. The actual pace of manufacturing footprint change has been real, but meaningfully slower and more selective than the political and marketing rhetoric surrounding it would suggest.
Where Reshoring Has Actually Happened
- High-value, lower-volume categories — specialized implants and precision instrumentation — have seen more genuine reshoring, since the manufacturing cost differential matters less relative to the product's total value
- Government and defense-adjacent supply chains have moved faster on reshoring given explicit policy mandates around domestic sourcing for certain federal and military healthcare supply
- Nearshoring to Mexico has outpaced true domestic reshoring for many mid-complexity categories, offering meaningful tariff and logistics advantages over Asian manufacturing without the full cost premium of U.S.-based production
Where It Hasn't
High-volume, low-margin commodity categories — gloves, basic PPE, standard IV supplies — remain overwhelmingly manufactured in Asia, since the labor cost differential for these categories is large enough that even substantial tariffs haven't yet made domestic production commercially competitive at scale.
What Buyers Should Actually Expect
Procurement teams should treat reshoring as a genuine but partial and category-specific trend rather than assuming their overall supply base is meaningfully de-risked from Asian manufacturing concentration. A realistic sourcing strategy accounts for continued heavy reliance on Asian-manufactured commodities for the foreseeable future, layered with more diversified sourcing for higher-value categories where reshoring economics genuinely work.
Facilities tracking manufacturing origin diversity can review sourcing options across Healix Medical Supply's supply catalog.
